secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001654954-23-005946
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin updates on PL9643 dry eye Phase 3 lead-in data and PL8177 UC data
-------------------------------------------------------------------------

- PL9643 lead-in data from MELODY-1 Phase 3 shows excellent ocular tolerability and broad efficacy on dry eye signs/symptoms.
- PL8177 preclinical data in rat UC models reduces colonic damage; oral formulation delivers to colon without systemic absorption.
- Phase 2 study PL8177-205 for UC enrolling; interim and topline data expected in 2H2023.
- KOL webinar replay with Dr. Stouch, Ousler, Raizman available on Palatin website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423005946/0001654954-23-005946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423005946/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-005946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer